3,4-二氢喹啉-2(1H)-酮衍生物的设计合成及抗精神分裂活性研究

目的 设计合成3,4-二氢喹啉-2(1H)-酮类化合物,考察其对D2、5-HT2A、5-HT1A受体的亲和力,并对代表化合物进行体内抗精神分裂活性测试.方法 7-羟基-3,4-二氢喹啉-2(1H)-酮与二卤代烷进行O-烷基化反应,再与相应的哌啶衍生物反应得到目标产物(Ⅰ1～Ⅰ11);对目标化合物进行了D2、5-HT2A...     

7-甲氧基-4-(2-甲基-4-喹唑啉基)-3,4-二氢喹噁啉-2(1H)-酮的合成工艺改进

目的:改进7-甲氧基-4-(2-甲基-4-喹唑啉基)-3,4-二氢喹噁啉-2(1H)-酮的合成工艺。方法:以2-甲基-4(3H)-喹唑啉酮为起始原料,通过氯代、亲核取代、二芳胺烷基化和硝基还原环合等反应对7-甲氧基-4-(2-甲基-4-喹唑啉基)-3,4-二氢喹噁啉-2(1H)-酮的合成工艺进行改进,并考察其收率。结果:7-甲氧基-4-(2-甲基-4-喹唑啉基)-3,4-二氢喹噁啉-2(1H)-酮的结构经核磁共振氢谱和电喷雾质谱确证,总收率为43.5%,较改进前的20.2%提高了23.3%。结论:改进后的工艺更简单,条件更温和,适合实验室研究的批量制备。     

反式-八氢-1H-吲哚-2-羧酸苄酯盐酸盐的合成

环己酮与丙烯腈经Micheal加成环合得3,4,5,6,7,8-六氢喹啉-2(1H)-酮,经甲酸/甲酸钠还原、氯代、选择性脱氯、重排后得反式-八氢-1H-吲哚-2-羧酸,再经苄基化、手性分离和成盐反应得到4个反式-八氢-1H-吲哚-2-羧酸苄酯盐酸盐。     

4-(4-甲氧基苯基)-3,4-二氢-2(1H)-喹啉酮的合成及抗惊厥作用研究

目的筛选抗惊厥活性的化合物,寻找新型抗癫痫药物。方法以肉桂酸为原料,对其化学结构进行优化,合成了4-(4-甲氧基苯基)-3,4-二氢-2(1H)-喹啉酮。采用最大电休克发作实验(MES)测定其抗癫痫活性。结果采用红外光谱、核磁共振氢谱和质谱确定了化学结构。经药理活性筛选发现4-(4-甲氧基苯基)-3,4-二氢-2(1H)-喹啉酮具有抗惊厥作用。结论本合成路线简单、产物易分离,为开发新的抗癫痫药物提供了新思路。     

6,7-二氟-4-羟基-2-甲氧甲硫基-3-喹啉羧酸乙酯的合成

3,4-二氟苯胺在三乙胺存在下与二硫化碳生成芳基取代的二硫代氨基甲酸后与氯甲酸乙酯反应得到3,4-二氟苯基异硫氰酸酯,先后与由丙二酸二乙酯在无机碱中成的盐和氯甲基甲醚反应后加热环合,得到氟喹诺酮类抗菌剂普卢利沙星的中间体6,7-二氟-4-羟基-2-甲氧甲硫基-3-喹啉羧酸乙酯,总收率85.7%.     

2-氯喹啉-3-甲醛缩氨基胍衍生物的合成及其抗炎活性研究

目的设计合成具有抗炎活性的2-氯喹啉-3-甲醛缩氨基胍类化合物。方法以6-羟基-3,4-二氢-2-喹啉酮为原料,与氯苄进行亲核取代反应得到中间体6-取代苄氧基-3,4-二氢-2-喹啉酮,该中间体经VilsmeierHaack反应得到2-氯-6-苄氧基-喹啉-3-醛类化合物,最后与氨基胍碳酸盐反应得到目标化合物;采用二甲苯诱导小鼠耳肿胀实验测定目标化合物的抗炎活性。结果与结论共合成了13个化合物,其中5个是未见报道的新化合物,其结构均经MS、IR、~1H-NMR和~(13)C-NMR谱确证。活性评价结果显示,该系列化合物均具有较好的抗炎活性。其中,化合物5a活性最好,在100 mg·kg~(-1)剂量下,腹腔注射给药时抑制率达到94.01%,优于阳性对照药布洛芬(39.56%)。     

月桂酰阿立哌唑合成工艺改进

以7-{4-[4-(2,3-二氯苯基)-l-哌嗪基]丁氧基}-3,4-二氢-2(1H)-喹啉酮（2）为起始原料，与甲醛水溶液进行羟基亚甲基化反应合成中间体7-{4-[4-(2,3-二氯苯基)哌嗪-1-基]丁氧基}-1-(羟甲基)-3,4-二氢喹啉-2(1H)-酮（3），然后再与月桂酸进行酯化反应得到（7-{4-[4-(2,3-二氯苯基)-1-哌嗪基]丁氧}-3,4-二氢-2-氧-1(2H)-喹啉基）甲酯（1）。本研究建立的合成路线操作简单，原料易得，总收率约62%，最终化合物1的纯度在99.9%以上，具有工业化生产的前景。     

普卢利沙星的合成

用3,4-二氟苯胺制得6,7-二氟-4-羟基-2-甲氧甲硫基喹啉-3-羧酸乙酯,在乙醇中与盐酸反应得到巯基化合物后,经与1,1-二碘乙烷环合、与哌嗪缩合、酸性水解得到6-氟-1-甲基-4-氧代-7-(1-哌嗪基)-1H,4H-[1,3]硫氮杂环丁烷并[3,2-a]喹啉-3-羧酸,最后与由3-羟基-2-丁酮和三光气反应后溴代得到的4-溴甲基-5-甲基-1,3-二噁环戊烯-2-酮缩合,得到氟喹诺酮类抗菌药普卢利沙星,总收率26%(以3,4-二氟苯胺计).     

4-甲基-香豆素及4-甲基喹啉-2(1H)-酮的7位羟基、巯基与炔丙基卤代物的不同反应性

目的合成具有抗HIV活性的三环杂环化合物的关键中间体.方法 7-羟基-4-甲基-香豆素、7-羟基-4-甲基喹啉-2(1H)-酮、7-巯基-4-甲基-香豆素分别与3-氯-3-甲基-1-丁炔、3-溴丙炔反应得到相应产物,其结构经波谱确证.结果 4-甲基-香豆素的7位羟基发生正常的双分子亲核取代反应(SN2),得到炔丙基醚产物4、7和10,进一步热环合得到三环杂环化合物5、8和11;7-巯基-4-甲基-香豆素、7-巯基-4-甲基喹啉-2(1H)-酮与3-氯-3-甲基-1-丁炔反应分别得丙二烯醚双分子亲核取代反应(SN2′)产物聚集双键硫醚化合物12和14,且不能进一步热环合成三环杂环.结论 4-甲基-香豆素及4-甲基喹啉-2(1H)-酮的7位羟基、巯基与炔丙基卤代物表现出不同的反应性.     

5-羟基-6-甲氧基-2-苄基-3,4-二氢异喹啉-1-酮的合成

目的研究5-羟基-6-甲氧基-3,4-二氢异喹啉-1-酮衍生物的合成方法。方法以异香草酸甲酯为原料,通过烯丙基醚化、Claisen重排、氧化、西佛碱的制备、还原、分子内酯的胺解6步反应合成了5-羟基-6-甲氧基-2-苄基-3,4-二氢异喹啉-1-酮(1),总收率达55.0%。Schiff碱的制备、还原、酯的胺解3步在"一锅"内完成。结果合成了新的3,4-二氢异喹啉-1-酮衍生物,其结构经IR和1HNMR确认。结论设计的合成路线具有反应条件温和、操作简便、反应总收率高等优点。     

阿立哌唑的合成

7-羟基-3,4-二氢-2（1H）-喹诺酮和4-溴-1-丁醇经醚化制得7-（4-羟基丁氧基）-3,4-二氢-2（1H）-喹诺酮，再经磺酰化、1-（2，3-二氯苯基）哌嗪取代制得抗精神病药阿立哌唑，总收率77．5％。     

7-羟基-3,4-二氢-2(1H)-喹啉酮的合成及两个副产物的分离确证

目的 改进7-羟基-3，4-二氢-2（1H）-喹啉酮的合成方法。方法 以间氨基苯甲醚为原料，经N-酰化和分子内傅-克烃化反应合成。结果 合成了目标化合物，两步反应的总收率为59％，并且分离出第二步反应的两个副产物，它们的结构经波谱确证。结论 改进的合成方法适用于工业化生产。     

Synthesis and antimicrobial activity of azasteroid-type compounds and related systems. Effect of hydrophilic and lipophilic groups on activity.

Pyrazole-, pyrazolone- and isoxazole-containing systems were prepared from 3,4-dihydro-6-(hexyloxy)-1(2H)-naphthalenone, 3,4-dihydro-6-(hexadecyloxy)-1(2H)-naphthalenone,3,4-dihydro-6(2-dimethylaminoethyloxy)-1-(2H)-naphthalenone, 3,4-dihydro-7-hexyloxy-1(2H)-phenanthrone, and 3,4-dihydro-7-(2-dimethylaminoethyloxy)-1(2H)-phenanthrone. A number of compounds derived from 7, 8-dihydro-5(6H)-quinolinone were also synthesized and characterized. Both hydrophilic and lipophilic groups were incorporated into certain systems as well as cidal groups. The compounds were screened for their in vitro inhibitory activity against Bacillus subtilis and Pseudomonas fluorescens. Structure-acitivity relationships among the molecular systems are discussed.     

阿立哌唑的合成

间氨基酚和3-氯丙酰氯制得的酰胺在无水三氯化铝作用下环合得7-羟基-3,4-二氢-2(1H)-喹诺酮,与1,4-二溴丁烷成醚后与1-(2,3-二氯苯基)哌嗪进行取代反应制得抗精神病药阿立哌唑,总收率25%.     

6-(4-酰基-1-哌嗪乙酰氨基)-3,4-二氢-2(1H)-喹啉酮类化合物的合成及正肌力活性初探

目的 :寻找具有正性肌力活性的化合物。方法 :根据文献报道的二氢喹啉酮类正性肌力药物的结构特点 ,设计、合成了其类似物。以苯胺为起始原料经多步合成 ,对所得化合物用离体豚鼠心脏与主动脉观察了心肌收缩力、扩血管作用及心率。结果 :合成了 1 0个 6 ( 4 酰基 1 哌嗪乙酰氨基 ) 3 ,4 二氢 2 ( 1H) 喹啉酮类化合物 ( 4a～ 4j) ,均为未见文献报道的化合物。结论 :初步药理试验表明 ,化合物 ( 4h)显示了正性肌力及扩血管活性。     

Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol.

Cilostazol (OPC-13013; 6-[4-(1-cyclohexl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone) is widely used as an antiplatelet vasodilator agent. In vitro, the hydroxylation of the quinone moiety of cilostazol to OPC-13326 [6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-4-hydroxy-2(1H)-quinolinone], is the predominant route, and the hydroxylation of the hexane moiety to OPC-13217 is the second most predominant route. This study was carried out to identify and kinetically characterize the human cytochrome P450 (P450) isozymes responsible for the formation of the two major metabolites of cilostazol, namely, OPC-13326 and OPC-13217 [3,4-dihydro-6-[4-[1-(cis-4-hydroxycyclohexyl)-1H-tetrazol-5-yl)butoxy]-2(1H)-quinolinone)]. In in vitro studies using 14 recombinant human P450 isozymes, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP2J2, CYP3A4, CYP3A5, and CYP4A11, cilostazol was metabolized to OPC-13326 mainly by CYP3A4 (K(m) = 5.26 muM, intrinsic clearance (CL(int)) = 0.34 microl/pmol P450/min), CYP1B1 (K(m) = 11.2 microM, CL(int) = 0.03 microl/pmol P450/min), and CYP3A5 (K(m) = 2.89 microM, CL(int) = 0.05 microl/pmol P450/min) and to OPC-13217 mainly by CYP3A5 (K(m) = 1.60 microM, CL(int) = 0.57 microl/pmol P450/min), CYP2C19 (K(m) = 5.95 microM, CL(int) = 0.16 microl/pmol P450/min), CYP3A4 (K(m) = 5.35 microM, CL(int) = 0.10 microl/pmol P450/min), and CYP2C8 (K(m) = 33.8 microM, CL(int) = 0.009 microl/pmol P450/min). The present study showed that the two major metabolites of cilostazol in vitro, namely, OPC-13326 and OPC-13217, are mainly catalyzed by CYP3A4 and CYP3A5, respectively.     

Synergy between a NR2B receptor antagonist DHQ and 3-methyl-gabapentin in mice with neuropathic pain

The synergistic effect of a selective NR2B NMDA receptor antagonist, (-)-(R)-6-{2-[4-(3-Fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl-3,4-dihydro-2(1H)-quinolinone (DHQ), and a alpha 2 delta ligand, 3-methyl-gabapentin (3M-GBP), was investigated in the mouse partial sciatic nerve model. The interaction was observed after administration of DHQ and 3M-GBP combination at fixed dose ratios of 1:10 and 1:30 and the dose-response curves shifted approximately 13- and 17-fold leftward, respectively, from the theoretical additive values. However, a fixed dose ratio of 1:50 resulted only in an additive effect. These results indicate the synergistic interaction between DHQ and 3M-GBP in this animal model of neuropathic pain.     

Synthesis and biological studies of triazolo-/thiadiazolo-benzoxazines

Diethyl bromomalonate (2) with an equimolar amount of 2-aminophenol (1) in the presence of sodium fluoride undergoes a cyclization reaction to form 2H,4H-2-ethoxycarbonyl-3,4-dihydro-3-oxo-1,4-benzoxazine (3). Furthermore, compound 3 undergoes a condensation reaction with hydrazine hydrate in the presence of methanol to yield 2H,4H-2-hydrazinocarbonyl-3,4-dihydro-3-oxo-1,4-benzoxazine (4), which on further reaction with aryl isothiocyanates gave 2H,4H-2-[ (4'-substituted)-phenylthiosemicarbazino]-carbonyl-3,4-dihydro-3-oxo-1,4-benzoxazine (5). Compound 5 on treatment with NaOH, cone. H2SO4 and diethylmalonate (6). afforded 2H,4H-2-[2'H-3'-thioxo-4'-substituted phenyl-1',2',4'-triazole-5-yl]- 3,4-dihydro-3-oxo-1,4benzoxazine (7). 2H,4H-2-[2'-amino-(substituted)-phenyl-1,3',4'-thiadiazol-5-yl]-3,4-dihydro-3-oxo-1,4-benzoxazine (8) and 2H,4H-2-[5'H-5'-dihydro-2'-thioxo-3'-phenyl-4',6'-dioxo-1,3-diazine]-aminocarbonyl-3,4-dihydro-3-oxo-1,4-benzoxazine (9), respectively. The synthesized compounds were investigated for their antibacterial activities against Gram positive as well as Gram negative bacteria with ampicillin trihydrate as standard drug. Structures have been elucidated on the basis of spectral and chemical analyses.     

A nonpeptide oxytocin receptor antagonist radioligand highly selective for human receptors

A novel, potent nonpeptide oxytocin receptor antagonist (1-(1-(2-(2,2,2-trifluoroethoxy)-4-(1-methylsulfonyl-4-piperidinyloxy) phenylacetyl)-4-piperidinyl)-3,4-dihydro-2(1H)-quinolinone) has been identified that can be labeled to high specific activity with [35S]. In binding studies, this compound exhibits sub-nanomolar affinity and a high degree of selectivity (900-1800-fold) for human oxytocin receptors compared to human vasopressin receptors. This compound appears suitable for studying the pharmacology of oxytocin receptors in human and nonhuman primate tissues, for which there is currently a paucity of highly selective tools. It may also be useful as a nonlabeled competitor or as a radioligand in autoradiographic studies of oxytocin receptor localization in these tissues.     

盐酸左布诺洛尔的合成工艺改进

以5-羟基-α-萘满酮与R-环氧氯丙烷反应，生成中间产物5-(2，3-环氧丙氧基)-α-萘满酮，不经分离，直接加入叔丁基胺反应得游离碱，盐酸成盐后得到了盐酸左布诺洛尔。该工艺路线可简化反应，使产率达到60％，光学纯度大于90％。